newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - CARDIFF ONCOLOGY INC

Hi, everyone. My name is Dejah Zang. I am on the Healthcare Investment Banking team at UBS, and thank you again for coming to our inaugural conference. We're really excited to be starting this and hosting everyone here at the Rosewood. I'm also excited to introduce Mani Mohindru, who is the CEO of Cardiff Oncology. All right. Is my mic working? Yes. Thank you, Dejay and the UBS team for inviting us to the conference and giving us the opportunity to tell our story. I will be telling you the value proposition in Cardiff, specifically as it relates to targeting colon cancer with PANDRAS mutations across the board, both NRAS, KRAS, with a very selective and tolerable PLK1 inhibitor that I'll be showing some data from. And I'm also very pleased to report that we got fast-track designation for this particular indication as well on Friday, and we put out the release this morning. So I will be making forward-looking statements during this presentation, so please refer to our SSE filings for the risk factors. So this slide kind of summarizes what we believe is a significant opportunity, bringing a new class of drugs to be a potential treatment-changing paradigm in the treatment of patients with RAS-mutated metastatic colorectal cancer in the first-line setting. And hopefully, I can convince you, based on the efficacy data that I'll be sharing with you, where we've had some very compelling efficacy trends we've seen in our randomized phase 2 trial controlled with the given chemo, the current chemo standard of care regimens, where we've shown around 70% plus overall response rate versus 42 or so that you see in the current standard of care arms, and almost 30% improvement versus the standard of carer. More importantly, while the median PFS data have matured in the control arm, the trial is ongoing, and we still haven't reached median PFS in the 30 milligram plus volfiri BEV, acknowledging that the study was not quite forward for PFS. And this is not just one trial where we've seen this efficacy. These data and the study, the study Was built on a prior study where, again, we had shown compelling efficacy in the second line in BEV-naive patients with this combination of chemo and RAS-mutated in that particular study, which is KRAS-mutated population. So we believe if we're successful in phase three, we have the potential to change practice and bring a new treatment to this disease where there's not been any kind of innovation for the last 20 years, and it remains an area of high and significant unmet need. In addition to colon, we've also seen some very promising signals in chronic myelomonocytic leukemia, which interestingly is also almost half the patients there are also ones that have RAS pathway-driven mutations. So it's interesting to see the signals, and there we've seen it in single agent in monotherapy. We've spent a good part of our year having regulatory interactions. We have had our end of phase 2 meeting successfully with the FDA, which has led to us designing a phase three trial. We've picked our dose and the chemo regimen with the blessings of the agency. And we are working earnestly towards starting our phase three trail. And, we have the potential to go for accelerated approval as well based on ORR and some durability, as well as full approval based on BFS. So, this is what the current, you know, metastatic RAS population looks like, metostatic colorectal cancer patients. Almost 50% of these patients have mutations in the RAS enzyme, and there are all kinds of mutations. With our PLK1 inhibitor, we are able to enroll any patient with any of these mutations, and the data that I'll share in the subsequent slide shows that our PLk1 inhibiter has the potential to be beneficial across the board. So almost 50% of metastatic colorectal patients have RAS mutations. But more interestingly, in the last 20-plus years, the only treatment available to these patients has been chemo, and then Avastin got added, which has now become generic as well. So there hasn't been really any new treatment for these patients who tend to do much poorly than their wild-type counterpart. And as you can see, you know, the overall survival is not very good for these patients. So I just want to spend a little bit of time explaining why a PLK1 inhibitor in DRAS-mutated disease. So, you Know, there's been some interesting research that has been done outside of Cardiff, which has shown that colon cancer specifically, the ones who harbor these RAS mutations, they rely heavily on PLK-1 for cell division. And in fact, PLK1 emerged as one of the first targets in a RNAi-based screen that was done in RAS-mutated colon cancers. So certainly, there is kind of a synthetic vulnerability here that we are addressing with our PLK1 inhibitor. The second thing is our drug, the PLK-1 inhibidor and vansetib, synergizes well with folfiri, specifically irenotekin, a topoisomerase inhibitor, not just in this study that I'm going to share the data from, but also in a prior study. But it has some mechanistic basis for it, which is by inhibiting HIF-1-alpha, which is an important angiogenic mechanistic pathway that the cancers rely on. So both irenotekin as well as our PLK1 inhibitor inhibit HIF1-alpha, which works along with bevacizumab, which is another agent that tackles angiogenesis. And all these things together are able to block the angiogensis pathways that are needed for cancers to grow. So, the next few slides would focus on data from our ongoing randomized phase two trial, CARDF004 study. We have shared a big chunk, a big decision-making chunk of our data at ASCO. It was as part of our oral presentation that was done by our PI, Dr. Lenz, Heinz-Josef Lenz out of USC. In this particular case, you know, we had the study so designed to pick a dose and a chemo regimen, which we did. We have 30 milligram Onvancitib in combination with Folfiri Bev that we would be taking into registrational trial. And I've already shared, you Know, the kind of compelling efficacy we see, both in terms of response rates as well as durability that the data continue to mature in the Onvincitib arm. And we gave a little update recently that all patients who now are still on the 30 milligram on vansetib plus folfuri arm have been on treatment for greater than 21 months. And the median PFS has been reached in the standard of care arm, which is very similar, both standard of careful fox and folfiri arms, which is very similiar to what has been historically reported at around 11 months. So this is the design of the study. This is a randomized controlled study where we were looking at two chemo regimens that are used in RAS-mutated population, a RAS mutated MCRC population in the front line, Folfiri Bev and Folfox Bev. And we picked two different doses as part of Project Optimus of the FDA to pick the best dose forward. Although going into the study, we knew that 30 milligram on Vansetiv was the best and optimal dose. We did prospectively select every patient for RAS mutations and made sure that there was no patient who had been previously exposed to bevacizumab. The dosing regimen works very well with the standard chemo regimens given. We give the drug for days 1 through 5, then there's a drug holiday for 9 days, and then days 15 through 19 of a 28-day cycle, with the primary endpoint being overall response rate, objective response rate. And the secondary endpoints being durability endpoints of duration of response and progression-free survival. This slide just shows very typical baseline characteristics. It's nothing unusual here. You know, the patients were all newly diagnosed metastatic colorectal patients with RAS mutations. There are a couple of things I do want to highlight. We did not exclude patients with liver mets. So we had patients who had liver metastasis at study entry, and there were also patients who had multi-organ mets involvement. And these are the kind of patients who have bad prognosis. You know, they're amongst the worst patients that you can include in these studies. And I'll share the data in the subsequent slides where you will see that our drug continues to show benefit even in these hard-to-treat patients. So at ASCO in June, we presented data cut as of March 18th, and that's highlighted in the box there, the yellow box. There were 14 patients still on trial at that time, and 13 of those 14 patients were on some combination of Onvancitib plus chemo. We've since given an update based off of what we are looking at at the end of September, and the data is still being cleaned, but we have eight patients who still continue to be on treatment, but importantly, only one patient still continues to be on standard of care, and three patients are on the 30 milligram arm and rest of them between 20 milligram Folfiri or 20 milligram Folfox arm. So this just shows that Onvancitib is doing something such that the patients on these Onvincitib arms continue to be on treatment for a long period of time, while most of the patients under standard of gear arms have come off treatment. So these are the waterfall plots that talk about how the treatment regimens of Onvancitib standard of care or Onvacitib plus standard of care benefits patients in terms of tumor reductions. I don't think I need to convince anyone about which panel looks like a clear winner. It is, of course, the Onvansitib 30 milligram plus Folfuri Bev arm, where we see an objective response rate of the order of 70 plus percent versus 42 percent what we see in the folfuri bev arm. Not only is the response rate high, but if you look at the depth of responses, they seem to be significantly better in the unvancitib 30 milligram arm in a dose-dependent manner from 20 to 30. If you move there, you not only get higher response rates, but you also get higher depth of response. And the arrowheads there show the patients who are still on treatment, and you can see majority of them lie in unvansitib plus folfiri arms. The other thing to highlight here are these diamonds on the top. It is a small study, but you can see that numerically there were more patients on the advanced tip 30 milligram plus 4-feri arm who went on to curative surgery. So the drug treatment was able to shrink the tumors enough such that these patients could be put on curative injury. surgery. So they left the study to get curative surgery, and they really weren't contributing to the PFS analysis that we had done in this early stage study. This, to me, is the most compelling slide. Certainly that this slide and the data on this slide gives us a lot of confidence as we move into phase three. So these so-called spider plots not just show tumor shrinkage, but they show tumor shrinking over time. And again, And if you can see very clearly, you know, on the right side panel, the panel on the rightmost side, on vansetib 30 milligram for theory, over time, you see that the tumors continue to shrink and they continue to, you know, be kept, the tumor shrinkage is maintained versus the control arm where you do get tumor shrinkage early on, but not very deep and not for very long. So these kind of data really translate into long-term benefit for patients, which we hope to capture in PFS and in subsequent studies as well. These are swimmer plots, which also give you a sense of how durable these responses are. again, if you focus on the lowermost panel, we have patients who are continuing on treatment for a very long period of time versus the standard of care arm of full which is the topmost panel and not just one or two patients, quite a few patients continue for a long period of time and also you get a sense of patients who went on surgery. So in the 30 milligram arm, you have quite a few patients where their tumors were reduced enough by the treatment such that they could be moved on to curative surgery. Otherwise, they probably would have continued to benefit as well for a longer period of time. So this is, you know, how do these responses translate into progression-free survival, something that obviously the regulators are looking for, the investors are looking forward. But I want to acknowledge that this is a small phase two study that was not powered for PFS analysis, yet we have seen compelling evidence of long-term durability in terms of progression-free survival. So this analysis actually includes combined standard-of-care arms in first-line setting, Folfuri Bev and Folfox Bev, and it's being compared to the combined 20 and 30 milligram Onvancitib plus Folfiri Bev treatment, keeping in mind that 20 milligram is a suboptimal dose. A few takeaways in this slide. The median PFS has been reached in the control arm of folfuribev combined with a decent number of patients in each arm, and which is approximately 11 months, very similar to what has been reported previously. So the study certainly worked. It showed median PHS in the controlled arms as has been historically reported. The median PFS at that time, and this was at the time of data cutoff that was presented at ASCO, median Pفس had not been reached in the 20-30 milligram control arm, and the hazard ratios looked pretty compelling. And we're quite pleased, whether we looked at investigator assessment or independent review-based assessment, we continue to see that our drug offers benefit on top of Folfiri-Bev standard of care arm in this difficult-to-treat patient population. Now, drilling down further on those data, if you just focus on the 30 milligram plus Folfuri-Bevs regimen, this is the dose and regimen we're taking forward in phase three. Again, both by independent assessment or investigator assessment, we see that we have not reached median BFS in the 30 milligram plus folfiri BEV regimen, even as of now. However, the median BFS has been reached in the control arm of folfieri BEV, and the hazard ratios are, again, though small study, but very compelling and promising, which makes it very compelling for us to take into phase three study. Now, this is an important analysis called forest plots, where if you see the dotted line, Anything to the left of the dotted line indicates that the treatment arm is favored versus anything to the right of this dotted line means that the outcomes are favored by the control arm. So if you look at the various baseline characteristics that we've tried to capture here, be it age or patients with liver mets or liver-only disease or multi-organ involvement, across the board, what you see is that on vansetib 30 milligram plus folfiri bev shows improvements across the boat whether or not the patients had liver mets, whether or no they were younger, whether or they had metastatic disease. So these are very compelling results, and this is based off of independent assessment of responses, that across the board, our drug shows some benefit even in this small study. And this is based on ORR. In the next slide, it's based on trends in PFS, acknowledging it's a small study. But again, across the boat, whether you look at patients who were young in age, whether they had liver disease, we see that our treatment of invancitib added on top of folfilib, BEV standard of care has the ability to show benefit in these patients. And also, the other way of looking at it is no one particular baseline characteristic influenced the outcomes of the study. So the other treatment regimen or the standard of gear regimen that we used, I'd shown only about FOLFERI so far. So this is focusing on FOLFOX-BEV. This is not the regimen that we are taking forward. However, we did see some responses, though they were not as compelling as we saw with Folfiri Bev. So, Invancitib offers best outcomes when given with Fulfiri Bev, even though we do see some response in the Folfox-Bev combination as well, as can be seen here. We get around 55 percent or so response rate with the 20 milligram dose given in combination with Folfox and a little bit higher than the standard of care with 30 milligram. However, the totality of these data show that while there is some benefit added when given on top of Folfax, the best benefit comes by combining on Bansatib 30 milligram with the Folfuri Bev regimen, and that's the one we plan to take forward in phase three. Now, you may wonder, why is this difference between the Folfiri and Folf ox arms? One, I want to start by saying that folferi regimen has proven to be beneficial with onvancitib 30 milligram in two studies, not one, but two. This study and a prior study that was done in second line where we saw the benefit with folferibev in patients who were bevacizumab naive. Mechanistically, it makes sense to combine our drug with topoisomerase 1 inhibitors like irinotecan. And for the reasons I'll discuss here, these tumors, specifically the colon cancer tumors, rely a lot on angiogenesis, new blood formation, new bloody vessel formation. And interestingly, both irinotecan and our drug, Onvancitib, inhibit this important enzyme known as HIF-1-alpha, which is involved in angiogensis in colon cancer. So in addition to BEV, you also try to inhibit angiogenesis by inhibiting HIF-1-alpha by both irenotecan and unvancitib, which is very synergistic, and hence what we see is outcomes in these clinical studies. The other important thing is that irerotecan is a DNA-damaging agent, and the mechanism by which it causes DNA damage, which is by single-stranded break, then leading to double-strended break. it is interesting that in this particular mechanistic pathway, PLK1 is actively involved in DNA damage repair. So if you cause DNA damage by an agent like irenotecan, and then you block the DNA damage-repair mechanism by an Asian such as Advancitib, you get two punches, and that is able to keep the cancer cells from growing. In contrast, if you look at oxaliplatin, One, oxaliplatin does not inhibit HIF-1-alpha to the same extent as irenotecan, so there is no synergy to be had on the HIF1-Alpha impact in causing anti-angiogenesis. And two, oxaliplatin damages the DNA by a mechanism where the role of PLK1 is non-existent or minimal. So there, again, there isn't a synergy to being had between unvancitib and oxaliplatin. So, I cannot tell you with 100% certainty which of these mechanisms is dominant in clinical outcomes, but the bottom line is it makes sense that irinotecan or topoisomerase 1-based combinations with unvancitib have the best outcomes, and that's what we've shown in our two clinical studies in metastatic colorectal patients with RAS mutations. The other less talked about attribute of our drug is its tolerability. So any agent that is given in first line in combination with chemo has to be well-tolerated for a long duration of time. And this slide, while it's quite busy, it highlights the fact that you really don't see any too many additive or new toxicities when Onvancitib is added to either the chemo regimen of Folfiri Bev or Folfox Bev. And I think this is the reason why FDA encouraged us earlier on in the development to move into first line. We can not only have an impact on overall response rate, but also keep giving the drug for a longer period of times in combination with chemotherapy and hopefully translate into much meaningful clinical benefit over a long period of time. So this slide just kind of summarizes where we stand versus the current standard of care. In the interest of time, I will try to go quickly over this slide. You know, the agents that got added on to chemo was mainly Bev in the last 20-plus years. And you can see that while Bevacizumab had an impact on durability in terms of BFS benefit, it really didn't have too much impact on overall response rate. whether it was combined with, you know, double it, two chemos, or whether it was combined three chemos. The impact was more on progression-free survival with little impact on objective response rates. However, when we added on vansetib to the fol-feribet regimen, we not only see an impact on overall response rates, but we are looking at, while the data starts still maturing, we are looking at a long-term benefit on progression-free survival. So certainly, this gives you a context as to the clinical benefit we believe on vansetib can provide when added on top of the right chemo regimen, whether you look at response rates, whether You look at long-time durability as measured by hazard ratios and PFS. So based on the totality of the data, we've had a very busy year interacting with the US FDA as well as European regulators. And this slide is a result of many such interactions where we've taken FDA's feedback and come out with our phase three plans. So a couple of things that I want to highlight. The enrollment criteria are very similar to what we had in our phase two that is still ongoing, the CARDF004 study. We will be prospectively enrolling all patients with all kinds of RAS mutations, so almost like a PAND-RAS patient selection criteria, and then would be comparing on Vansatib 30 milligram, which is the best dose we saw with Folfiri Bev to Folfuri Bev regimen alone. And the study is adequately powered for PFS, which ist for full approval, but the FDA has also allowed us to take a look at the overall response rate data for going into accelerated approval should the data be compelling. So we are very lucky that we have the ability to go for accelerated approval as well as full approval within the same study. And with the new FAST-TRACK designation that we just announced, it should give us the abilityto interact with the FDA on a much more frequent basis as we roll this study forward. We've also had interactions with theFDA on manufacturing, on companion diagnostic, and all of that have been going pretty well. And we feel that we're very well prepared to start the study pending funding, but we're also working with various, you know, we've picked a CRO and we're working towards even a staged initiation of this trial without wasting too much time in the first quarter of 27. This slide just highlights some of the competitive therapies that are also being developed in the first-line colon setting. None of this, to the best of our knowledge, is addressing the pan-RAS-mutated colorectal space. You know, we are specifically going for a label that is in the front line for patients with all kinds of RAS mutations in the metastatic colorector setting. The main competitors who are working in this space are going for a more more MSS population and not really picking patients with RAS mutations, and they are either PD-1 VEGFs or PD-L1 Vegefs, and the TGF beta receptor 2 and PD-2 by specific G12C inhibitors are a very, very small fraction of the entire RAS mutant population. I just want to spend the next few minutes talking about where else can this be applied. Certainly, I've shared what we believe is very compelling data in the first-line rasmutated colorectal space. We have some very promising signals that we are seeing emerging out of an investigator-initiated study in relapsed refractory chronic myelomonocytic leukemia, a very bad disease with very small overall survival in the order of six to eight months in the relapsed refractory setting, and we are seeing some compelling monotherapy signals there, and we're also investigating in other places. By the way, we also recently received orphan drug designation for both CMML and small cell lung cancer where we've seen early signals of monotherapy activity. This slide just shows some of the CMML data that were presented last year's ASH. There will be an updated presentation at this year's American Society of Hematology meeting coming up in December. Here, I think you start seeing responses in the order of around 40%. This study is being conducted at Mayo Clinic, Rochester, and there's nothing really approved for these patients in the relapsed refractory setting, a very bad disease with very poor outcomes. So it's encouraging for us to see that there are other places where we can go, and 50% of these patients have RAS pathway mutations. In the last minute or so, I would like to end by sharing, you know, the achievements that the team at Cardiff has been working towards. You know, the trial, the Cardiff 004 trial is still ongoing, so we are executing on it while we've had actionable data that have emerged. We presented at ASCO, worked with the regulators, have a phase three plan and a path forward. And we are very, very happy to receive the fast track designation that was shared with us from the agency this past Friday. And we look forward to sharing data from CMML study at ASH and also our awaiting feedback from the European regulators. We have cash of around 34 million that we've announced as of end of third quarter which will last us to the end of the third quarter of 2027 and and we are working earnestly towards getting our phase three up and running in some shape and for some shape or form even in a staged manner in the first quarter of next year With that, I will end the presentation here, and thank you to everyone for your attention.

Company
CARDIFF ONCOLOGY INC
Keywords
CARDIFF ONCOLOGY INC